Ongoing trials include adagrasib plus cetuximab for KRAS G12C in colorectal cancer (CRC) (phase III) and BLU-945, a fourth-generation EGFR inhibitor, for osimertinib-resistant NSCLC (phase I/II) [191]. Here, KRAS is linked to colorectal carcinoma.